2023
Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
Silva-Rodríguez J, Labrador-Espinosa M, Moscoso A, Schöll M, Mir P, Grothe M, Weiner M, Aisen P, Petersen R, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Perrin R, Shaw L, Khachaturian Z, Carrillo M, Potter W, Barnes L, Bernard M, González H, Ho C, Hsiao J, Jackson J, Masliah E, Masterman D, Okonkwo O, Perrin R, Ryan L, Silverberg N, Fleisher A, Weiner M, Sacrey D, Fockler J, Conti C, Veitch D, Neuhaus J, Jin C, Nosheny R, Ashford M, Flenniken D, Kormos A, Green R, Montine T, Conti C, Petersen R, Aisen P, Rafii M, Raman R, Jimenez G, Donohue M, Gessert D, Salazar J, Zimmerman C, Cabrera Y, Walter S, Miller G, Coker G, Clanton T, Hergesheimer L, Smith S, Adegoke O, Mahboubi P, Moore S, Pizzola J, Shaffer E, Sloan B, Beckett L, Harvey D, Donohue M, Jack C, Forghanian-Arani A, Borowski B, Ward C, Schwarz C, Jones D, Gunter J, Kantarci K, Senjem M, Vemuri P, Reid R, Fox N, Malone I, Thompson P, Thomopoulos S, Nir T, Jahanshad N, DeCarli C, Knaack A, Fletcher E, Harvey D, Tosun-Turgut D, Chen S, Choe M, Crawford K, Yushkevich P, Das S, Jagust W, Koeppe R, Reiman E, Chen K, Mathis C, Landau S, Morris J, Perrin R, Cairns N, Householder E, Franklin E, Bernhardt H, Taylor-Reinwald L, Shaw L, Trojanowki J, Korecka M, Figurski M, Toga A, Crawford K, Saykin A, Nho K, Risacher S, Apostolova L, Shen L, Foroud T, Nudelman K, Faber K, Wilmes K, Weiner M, Thal L, Khachaturian Z, Hsiao J, Schneider L, Silbert L, Pawluczyk S, Lind B, Becerra M, Crissey R, Teodoro L, Kaye J, Dagerman K, Carter R, Spann B, Dolen S, Quinn J, Brewer J, Vanderswag H, Fleisher A, Ziolkowski J, Heidebrink J, Zbizek-Nulph L, Lord J, Zbizek-Nulph L, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Villanueva-Meyer J, Pavlik V, Pacini N, Lamb A, Kass J, Doody R, Shibley V, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Mintz A, Ances B, Morris J, Winkfield D, Carroll M, Stobbs-Cucchi G, Oliver A, Creech M, Mintun M, Schneider S, Geldmacher D, Love M, Griffith R, Clark D, Brockington J, Marson D, Grossman H, Goldstein M, Greenberg J, Mitsis E, Shah R, Lamar M, Duara R, Greig-Custo M, Rodriguez R, Albert M, Onyike C, Farrington L, Rudow S, Brichko R, Kielb S, Smith A, Raj B, Fargher K, Sadowski M, Wisniewski T, Shulman M, Faustin A, Rao J, Castro K, Ulysse A, Chen S, Sheikh M, Singleton-Garvin J, Doraiswamy P, Petrella J, James O, Wong T, Borges-Neto S, Karlawish J, Wolk D, Vaishnavi S, Clark C, Arnold E, Smith C, Jicha G, Khouli R, Raslau F, Lopez O, Oakley M, Simpson D, Porsteinsson A, Martin K, Kowalski N, Keltz M, Goldstein B, Makino K, Ismail M, Brand C, Thai G, Pierce A, Yanez B, Sosa E, Witbracht M, Kelley B, Nguyen T, Womack K, Mathews D, Quiceno M, Levey A, Lah J, Hajjar I, Cellar J, Burns J, Swerdlow R, Brooks W, Silverman D, Kremen S, Apostolova L, Tingus K, Lu P, Bartzokis G, Woo E, Teng E, Graff-Radford N, Parfitt F, Poki-Walker K, Farlow M, Hake A, Matthews B, Brosch J, Herring S, van Dyck C, Mecca A, Good S, MacAvoy M, Carson R, Varma P, Chertkow H, Vaitekunis S, Hosein C, Black S, Stefanovic B, Heyn C, Hsiung G, Kim E, Mudge B, Sossi V, Feldman H, Assaly M, Finger E, Pasternak S, Rachinsky I, Kertesz A, Drost D, Rogers J, Grant I, Muse B, Rogalski E, Robson J, Mesulam M, Kerwin D, Wu C, Johnson N, Lipowski K, Weintraub S, Bonakdarpour B, Pomara N, Hernando R, Sarrael A, Rosen H, Miller B, Perry D, Turner R, Johnson K, Reynolds B, MCCann K, Poe J, Sperling R, Johnson K, Marshall G, Yesavage J, Taylor J, Chao S, Coleman J, White J, Lane B, Rosen A, Tinklenberg J, Belden C, Atri A, Spann B, Clark K, Zamrini E, Sabbagh M, Killiany R, Stern R, Mez J, Kowall N, Budson A, Obisesan T, Ntekim O, Wolday S, Khan J, Nwulia E, Nadarajah S, Lerner A, Ogrocki P, Tatsuoka C, Fatica P, Fletcher E, Maillard P, Olichney J, DeCarli C, Carmichael O, Bates V, Capote H, Rainka M, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Perrin A, Burke A, Scharre D, Kataki M, Tarawneh R, Kelley B, Hart D, Zimmerman E, Celmins D, Miller D, Ponto L, Smith K, Koleva H, Shim H, Nam K, Schultz S, Williamson J, Craft S, Cleveland J, Yang M, Sink K, Ott B, Drake J, Tremont G, Daiello L, Drake J, Sabbagh M, Ritter A, Bernick C, Munic D, Mintz A, O’Connelll A, Mintzer J, Wiliams A, Masdeu J, Shi J, Garcia A, Sabbagh M, Newhouse P, Potkin S, Salloway S, Malloy P, Correia S, Kittur S, Pearlson G, Blank K, Anderson K, Flashman L, Seltzer M, Hynes M, Santulli R, Relkin N, Chiang G, Lee A, Lin M, Ravdin L, Weiner M, Aisen P, Petersen R, Weiner M, Aisen P, Petersen R, Green R, Harvey D, Jack C, Jagust W, Morris J, Saykin A, Shaw L, Toga A, Trojanowki J, Neylan T, Grafman J, Green R, Montine T, Weiner M, Petersen R, Aisen P, Jimenez G, Donohue M, Gessert D, Salazar J, Zimmerman C, Walter S, Adegoke O, Mahboubi P, Hergesheimer L, Danowski S, Coker G, Clanton T, Pizzola J, Shaffer E, Nguyen-Barrera C, Neylan T, Hayes J, Finley S, Harvey D, Jack C, Bernstein M, Borowski B, Gunter J, Senjem M, Kantarci K, Ward C, Tosun-Turgut D, Chen S, Landau S, Koeppe R, Foster N, Reiman E, Chen K, Morris J, Perrin R, Franklin E, Shaw L, Trojanowki J, Korecka M, Figurski M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Faber K, Kim S, Nho K, Wilmes K, Schneider L, Pawluczyk S, Becerra M, Teodoro L, Dagerman K, Spann B, Brewer J, Vanderswag H, Fleisher A, Stern Y, Honig L, Mintz A, Shah R, Sood A, Blanchard K, Fleischman D, Arfanakis K, Duara R, Varon D, Greig M, Doraiswamy P, Petrella J, James O, Borges-Neto S, Wong T, Porsteinsson A, Goldstein B, Martin K, Thai G, Pierce A, Reist C, Yanez B, Sosa E, Witbracht M, Sadowsky C, Martinez W, Villena T, Rosen H, Perry D, Turner R, Johnson K, Reynolds B, MCCann K, Poe J, Sperling R, Johnson K, Marshall G, Belden C, Atri A, Spann B, Clark K, Zamrini E, Sabbagh M, Obisesan T, Ntekim O, Wolday S, Nwulia E, Nadarajah S, Johnson S, Asthana S, Carlsson C, Peskind E, Petrie E, Li G, Yesavage J, Taylor J, Chao S, Coleman J, White J, Lane B, Rosen A, Tinklenberg J, Lin M, Chiang G, Ravdin L, Relkin N, O’Connelll A, Mintzer J, Wiliams A, Mackin S, Aisen P, Raman R, Jimenez-Maggiora G, Donohue M, Gessert D, Salazar J, Zimmerman C, Walter S, Adegoke O, Mahboubi P, Mackin S, Weiner M, Aisen P, Raman R, Jack C, Landau S, Saykin A, Toga A, DeCarli C, Koeppe R, Green R, Drake E, Weiner M, Aisen P, Raman R, Donohue M, Mackin S, Nelson C, Bickford D, Butters M, Zmuda M, Jack C, Rochester C, Bernstein M, Borowski B, Gunter J, Senjem M, Kantarci K, Ward C, Reyes D, Koeppe R, Landau S, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Faber K, Nho K, Nudelman K, Mackin S, Rosen H, Nelson C, Bickford D, Au Y, Scherer K, Catalinotto D, Stark S, Ong E, Fernandez D, Butters M, Zmuda M, Lopez O, Oakley M, Simpson D. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology. Brain 2023 PMID: 37284793, DOI: 10.1093/brain/awad194.Peer-Reviewed Original ResearchLewy body pathologyFDG-PET patternsFDG-PET scansDisease dementiaAlzheimer's disease dementiaHypometabolism patternsDisease patientsDisease Neuroimaging InitiativeClinical diagnosisAMCI patientsADD patientsSubset of patientsSpecific clinical featuresFDG-PET imagingPresence of hallucinationsAlzheimer's disease patientsAlzheimer's disease biomarkersAmnestic mild cognitive impairmentDisease biomarkersMild cognitive impairmentAlzheimer's Disease Neuroimaging InitiativeGlucose hypometabolismClinical featuresLewy bodiesTau-PET
2021
Generation of parametric Ki images for FDG PET using two 5‐min scans
Wu J, Liu H, Ye Q, Gallezot J, Naganawa M, Miao T, Lu Y, Chen M, Esserman DA, Kyriakides TC, Carson RE, Liu C. Generation of parametric Ki images for FDG PET using two 5‐min scans. Medical Physics 2021, 48: 5219-5231. PMID: 34287939, DOI: 10.1002/mp.15113.Peer-Reviewed Original ResearchConceptsPopulation-based input functionDynamic FDG-PET scansFDG-PET scansFDG-PETSUV changesPET scansClinical practiceSolid lung nodulesClinical usefulnessLate scansBone marrowRegion of interestLung nodulesInput functionScansPatlak analysisKi imagesMin/T-testCorrelation coefficientTumorsSubjectsNodulesDynamic imagingPET
2020
A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL
Li X, Jemaa S, Carano R, Bengtsson T, Paulson J, Jansen G, Nielsen T, Hibar D. A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL. Blood 2020, 136: 28. DOI: 10.1182/blood-2020-134877.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaProgression-free survivalCurrent equity holderInternational Prognostic IndexFDG-PET scansProgression-free survival probabilityLow-risk groupHigh-risk groupBaseline FDG-PET scanHigh-risk patientsPredicting high-risk patientsFollicular lymphomaFL patientsPrognostic performanceF. Hoffmann-La RocheRadiomic featuresCHOP chemotherapyGALLIUM studyStratify patientsDe novo diffuse large B-cell lymphomaDLBCL populationDiffuse large B-cell lymphoma patientsHigh-risk patient subpopulationsInternational Prognostic Index modelLarge B-cell lymphoma
2018
FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease
Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease. NeuroImage Clinical 2018, 20: 572-579. PMID: 30186761, PMCID: PMC6120603, DOI: 10.1016/j.nicl.2018.08.006.Peer-Reviewed Original ResearchConceptsHealthy controlsDisease-related patternsParkinson's diseaseYahr stagePD patientsClinical trialsParkinson's disease-related patternFluorodeoxyglucose positron emission tomographyGender-matched healthy controlsEarly-stage Parkinson's diseaseMild PD patientsEarly-stage diseaseFDG-PET scansMotor symptom scoresPositron emission tomographyStage diseaseMotor symptomsSymptom scoresFDG-PETDisease stagePD progressionLentiform nucleusParacentral gyrusSymptom evaluationPD subjects
2015
Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals Of Oncology 2015, 26: 774-779. PMID: 25605745, PMCID: PMC4374388, DOI: 10.1093/annonc/mdv010.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaInternational Workshop CriteriaFDG-PET scansRefractory peripheral T-cell lymphomaBaseline FDG-PET scanCR/CRuT-cell lymphomaPositron emission tomographyConventional radiologyPET criteriaStable diseaseEnd pointFDG-PETConventional stagingPET statusResponse assessmentPivotal phase 2 trialEmission tomographyDeoxyglucose positron emission tomographyExploratory end pointsObjective response ratePET-positive diseasePrimary end pointProgression-free survivalPhase 2 study
2014
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
James E, Yao X, Cong X, Stein S, Kaley K, Hahn C, Cha C, Salem R, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: 256-256. DOI: 10.1200/jco.2014.32.3_suppl.256.Peer-Reviewed Original ResearchMetastatic pancreatic cancerAdvanced pancreatic cancerPancreatic cancerFebrile neutropeniaResponse rateEvaluable ptsProphylactic pegfilgrastimInterim analysisPhase II open-label studyGrade 3/4 toxicitiesOpen-label studyPhase II studyFDG-PET scansSimilar response ratesECOG PSNeoadjuvant FOLFIRINOXUnderwent resectionII studySurgical resectionUnacceptable toxicityPET responseFOLFIRINOXRetrospective analysisDose reductionLabel study
2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs 2010, 29: 1465-1474. PMID: 20499131, PMCID: PMC3042040, DOI: 10.1007/s10637-010-9455-x.Peer-Reviewed Original ResearchConceptsCastrate-resistant prostate cancerMetastatic castrate-resistant prostate cancerTaxane-refractoryPrimary endpointProstate cancerAdverse eventsProgression-free survivalPhase II studyTaxane-based regimensClinically significant activityFDG-PET scansLiver function testsFDG-PET imagingMetabolic responsePSA responseAggressive biologyEvidence of biological activityExploratory endpointsStudy drugSecondary endpointsPreclinical dataGastrointestinal hemorrhageFDG-PETMonth 6Pre-chemotherapy
2006
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
Lin N, Carey L, Liu M, Younger J, Come S, Bullitt E, Van Den Abbeele A, Li X, Hochberg F, Winer E. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Journal Of Clinical Oncology 2006, 24: 503-503. DOI: 10.1200/jco.2006.24.18_suppl.503.Peer-Reviewed Original ResearchBrain metastasesBreast cancerObjective responsePrimary endpointCNS lesionsCNS diseaseCentral nervous system metastasesVolumetric declinesCentral radiology reviewProgressive brain metastasesNervous system metastasesPhase II trialEfficacy of lapatinibMetastatic breast cancerFDG-PET scansMean age 52Analysis of QOLCommon AEsEligible patientsMeasurable diseasePo bidII trialPrior radiationRECIST criteriaSecondary endpoints
1998
Decreased brain glucose utilization in patients with Cushing's disease.
Brunetti A, Fulham M, Aloj L, De Souza B, Nieman L, Oldfield E, Di Chiro G. Decreased brain glucose utilization in patients with Cushing's disease. Journal Of Nuclear Medicine 1998, 39: 786-90. PMID: 9591575.Peer-Reviewed Original ResearchConceptsCushing's diseaseCerebral glucose metabolismGlucose metabolismPET scansDecreased brain glucose utilizationIncreased plasma glucocorticoid levelsRadiotracer 18F-fluorodeoxyglucoseFDG-PET scansGlucocorticoid levelsAge-matched normal control subjectsFDG-PET studiesNormal control subjectsPlasma glucocorticoid levelsIncreased glucose metabolismIncreased glucocorticoid levelsMeasurements of cerebral glucose metabolismPostsurgery valuesDecreased cerebral glucose metabolismPituitary adenomasAbnormal cerebral glucose metabolismSurgical removalBrain glucose utilizationControl subjectsCentral actionCushing
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply